We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

PAREXEL Strengthens Commitment to Global Biopharmaceutical Workforce

News   Apr 10, 2015

 
PAREXEL Strengthens Commitment to Global Biopharmaceutical Workforce
 
 
Advertisement
 

RELATED ARTICLES

Phase 1 Study of Novel Oral Antiviral Against SARS-CoV-2 Initiated

News

Pfizer's oral antiviral clinical candidate PF-07321332, a SARS-CoV2-3CL protease inhibitor, is progressing to Phase 1 testing following preclinical testing demonstrating potent in vitro anti-viral activity against SARS-CoV-2.

READ MORE

New “Weapon” Against Cancer Enters Clinical Trials

News

Scientists are aiming to validate an innovative radiotherapy as part of a safe, more effective and potentially less costly treatment for bladder cancer.

READ MORE

Reviving Failed Antibody Treatments for Solid Tumors

News

Lab-engineered antibodies remain the core facilitator of immunotherapies and CAR T-cell therapies. But these therapies have proved less effective against solid tumors, compared with other cancers. Now, researchers have uncovered why some of these antibody approaches appear to effectively kill cancer tumors in laboratory tests but are ineffective in clinical trials.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE